scholarly journals CD36 identified by weighted gene co-expression network analysis as a hub candidate gene in lupus nephritis

PeerJ ◽  
2019 ◽  
Vol 7 ◽  
pp. e7722 ◽  
Author(s):  
Huiying Yang ◽  
Hua Li
Keyword(s):  
Network Analysis ◽  
Lupus Nephritis ◽  
Candidate Gene ◽  
Lupus Erythematosus ◽  
Maximal Clique ◽  
Gene Expression Omnibus ◽  
Urgent Task ◽  
Severe Manifestation ◽  
Stage Renal Disease ◽  
End Stage

Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus (SLE), which often progresses to end-stage renal disease (ESRD) and ultimately leads to death. At present, there are no definitive therapies towards LN, so that illuminating the molecular mechanism behind the disease has become an urgent task for researchers. Bioinformatics has become a widely utilized method for exploring genes related to disease. This study set out to conduct weighted gene co-expression network analysis (WGCNA) and screen the hub gene of LN. We performed WGCNA on the microarray expression profile dataset of GSE104948 from the Gene Expression Omnibus (GEO) database with 18 normal and 21 LN samples of glomerulus. A total of 5,942 genes were divided into 5 co-expression modules, one of which was significantly correlated to LN. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were conducted on the LN-related module, and the module was proved to be associated mainly with the activation of inflammation, immune response, cytokines, and immune cells. Genes in the most significant GO terms were extracted for sub-networks of WGNCA. We evaluated the centrality of genes in the sub-networks by Maximal Clique Centrality (MCC) method and CD36 was ultimately screened out as a hub candidate gene of the pathogenesis of LN. The result was verified by its differentially expressed level between normal and LN in GSE104948 and the other three multi-microarray datasets of GEO. Moreover, we further demonstrated that the expression level of CD36 is related to the WHO Lupus Nephritis Class of LN patients with the help of Nephroseq database. The current study proposed CD36 as a vital candidate gene in LN for the first time and CD36 may perform as a brand-new biomarker or therapeutic target of LN in the future.

scholarly journals Change of Renal Gallium Uptake Correlated with Change of Inflammation Activity in Renal Pathology in Lupus Nephritis Patients

2021 ◽  
Vol 10 (20) ◽  
pp. 4654
Author(s):  
Tsu-Yi Hsieh ◽  
Yi-Ching Lin ◽  
Wei-Ting Hung ◽  
Yi-Ming Chen ◽  
Mei-Chin Wen ◽  
...  
Keyword(s):  
Lupus Nephritis ◽  
Lupus Erythematosus ◽  
Activity Index ◽  
Left Kidney ◽  
Renal Pathology ◽  
Class Iii ◽  
Stage Renal Disease ◽  
End Stage ◽  
Active Inflammation ◽  
Histological Results

Background: Lupus nephritis (LN) often lead to end-stage renal disease in systemic lupus erythematosus patients. This study aimed to investigate the clinical application of renal gallium-67 scans for determining renal histological parameters in LN patients. Methods: Between 2006 and 2018, 237 biopsy-proven and 35 repeat biopsies LN patients who underwent renal gallium scans before or after biopsy were included for analysis. The classification and scoring of LN were assessed according to the International Society of Nephrology/Renal Pathology Society. A delayed 48-h gallium scan was performed and interpreted by semiquantitative methods using left kidney/spine (K/S) ratio. The renal histological results were compared with gallium uptake. Results: Out of 237 participants, 180 (76%) had proliferative LN. Baseline gallium left K/S ratio was significantly higher in class IV LN as compared to class III (median (interquartile range, IQR): 1.16 (1.0–1.3), 0.95 (0.9–1.1), respectively, p < 0.001). Furthermore, changes in gallium uptake between two biopsies were positively correlated with changes activity index (r = 0.357, p = 0.035), endocapillary hypercellularity (r = 0.385, p = 0.032), and neutrophils infiltration (r = 0.390, p = 0.030) in renal pathology. Conclusions: Renal gallium uptake is associated with active inflammation in LN. Changes in renal gallium uptake positively correlated with changes in activity index in renal pathology.

scholarly journals Lupus nephritis: clinical presentations and outcomes in the 21st century

Rheumatology ◽  
2020 ◽  
Vol 59 (Supplement_5) ◽  
pp. v39-v51 ◽  
Author(s):  
Michela Gasparotto ◽  
Mariele Gatto ◽  
Valentina Binda ◽  
Andrea Doria ◽  
Gabriella Moroni
Keyword(s):  
Lupus Nephritis ◽  
New Drugs ◽  
The Past ◽  
Disease Prognosis ◽  
Clinical Presentations ◽  
Retrospective Cohort Studies ◽  
Severe Manifestation ◽  
Stage Renal Disease ◽  
End Stage ◽  
Therapeutic Research

Abstract Lupus nephritis (LN) is a frequent and severe manifestation of SLE. Along the decades, the epidemiology of LN and its clinical presentation have been changing. However, even though retrospective cohort studies report a decreased mortality rate and an improvement in the disease prognosis, the percentage of patients progressing into end stage renal disease (ESRD) keeps steady despite the improvements in therapeutic strategies. Current in-use medications have been available for decades now, yet over the years, regimens for optimizing their efficacy and minimizing toxicity have been developed. Therapeutic research is now moving towards the direction of precision medicine and several new drugs, targeting selectively different pathogenetic pathways, are currently under evaluation with promising results. In this review, we address the main changes and persistent unmet needs in LN management throughout the past decades, with a focus on prognosis and upcoming treatments.

Histological predictors of renal outcome in lupus nephritis: the importance of tubulointerstitial lesions and scoring of glomerular lesions

Lupus ◽  
2018 ◽  
Vol 27 (9) ◽  
pp. 1455-1463 ◽  
Author(s):  
B Obrișcă ◽  
R Jurubiță ◽  
A Andronesi ◽  
B Sorohan ◽  
C Achim ◽  
...  
Keyword(s):  
Lupus Nephritis ◽  
Lupus Erythematosus ◽  
Kidney Biopsy ◽  
Renal Outcome ◽  
Predictors Of Outcome ◽  
End Point ◽  
Tubulointerstitial Lesions ◽  
Cox Proportional Hazard Regression ◽  
Stage Renal Disease ◽  
End Stage

Introduction Lupus nephritis (LN) affects nearly 60% of patients with systemic lupus erythematosus and up to 30% of them will progress to end-stage renal disease (ESRD), despite receiving aggressive immunosuppressive therapy. The prognostic value of ISN/RPS classification is controversial. Therefore, we aimed to identify clinical and pathological predictors of outcome in LN patients independent of this classification. Material and methods Thirty-seven patients with LN who underwent percutaneous kidney biopsy between 1997 and 2016 were included in this study. Twenty clinical and twenty histological variables were tested for their association with a composite end-point of doubling of serum creatinine, ESRD and death. Univariate and multivariate Cox proportional hazard regression analysis were performed to identify independent predictors of outcome. Results During a median follow-up period of 48 months (IQR: 17.5–120 months), 21.6% of patients reached the composite end-point. The overall survival rate of our cohort was 89% at one year, 86% at five years, 74% at 10 years and 64% at 20 years. Patients with Class IV LN showed the worst prognosis with 44% survival at 10 years, while those who additionally showed crescents and global sclerosis on kidney biopsy had an even lower survival of 21% and 0% at 10 years, respectively. After multivariate adjustment, we identified estimated glomerular filtration rate at baseline (HR, 0.91 per ml/min /1.73 m2; 95% CI, 0.84 to 0.99), 24-hour proteinuria at baseline (HR, 2.04 per g/d; 95% CI, 1.19 to 3.5), crescents (HR, 1.068 per %; 95% CI, 1.003 to 1.091), global sclerosis (HR, 1.036 per %; 95% CI, 0.984 to 1.091), presence of adhesions (HR, 9.2; 95% CI, 1.38 to 61.2) and tubulitis (HR, 13.1; 95% CI; 1.3 to 131) as independent predictors of outcome in our cohort of LN. Conclusions Our study identified glomerular (crescents, global sclerosis, adhesions) and tubulointerstitial (tubulitis) lesions, in addition to clinical variables (renal function, 24-hour proteinuria), as important predictors of renal outcome, independent of the ISN/RPS classification. We suggest that the ISN/RPS classification could be improved by a quantitative assessment of glomeruli with active and chronic lesions and by a greater emphasis given to tubulointerstitial lesions.

scholarly journals Punicalagin Ameliorates Lupus Nephritis via Inhibition of PAR2

2020 ◽  
Vol 21 (14) ◽  
pp. 4975
Author(s):  
Yohan Seo ◽  
Chin Hee Mun ◽  
So-Hyeon Park ◽  
Dongkyu Jeon ◽  
Su Jeong Kim ◽  
...  
Keyword(s):  
Lupus Nephritis ◽  
Cell Line ◽  
Lupus Erythematosus ◽  
High Throughput Screening ◽  
Intraperitoneal Administration ◽  
Kidney Injury ◽  
High Rate ◽  
Beneficial Effects ◽  
Stage Renal Disease ◽  
End Stage

Lupus nephritis (LN) is the most frequent phenotype in patients with systemic lupus erythematosus (SLE) and has a high rate of progression to end-stage renal disease, in spite of intensive treatment and maintenance therapies. Recent evidence suggests that protease-activated receptor-2 (PAR2) is a therapeutic target for glomerulonephritis. In this study, we performed a cell-based high-throughput screening and identified a novel potent PAR2 antagonist, punicalagin (PCG, a major polyphenol enriched in pomegranate), and evaluated the effects of PCG on LN. The effect of PCG on PAR2 inhibition was observed in the human podocyte cell line and its effect on LN was evaluated in NZB/W F1 mice. In the human podocyte cell line, PCG potently inhibited PAR2 (IC50 = 1.5 ± 0.03 µM) and significantly reduced the PAR2-mediated activation of ERK1/2 and NF-κB signaling pathway. In addition, PCG significantly decreased PAR2-induced increases in ICAM-1 and VCAM-1 as well as in IL-8, IFN-γ, and TNF-α expression. Notably, the intraperitoneal administration of PCG significantly alleviated kidney injury and splenomegaly and reduced proteinuria and renal ICAM-1 and VCAM-1 expression in NZB/W F1 mice. Our results suggest that PCG has beneficial effects on LN via inhibition of PAR2, and PCG is a potential therapeutic agent for LN.

scholarly journals Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression

Lupus ◽  
2020 ◽  
Vol 29 (9) ◽  
pp. 1011-1020
Author(s):  
Anadi Mahajan ◽  
Justyna Amelio ◽  
Kerry Gairy ◽  
Gavneet Kaur ◽  
Roger A Levy ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Nephritis ◽  
Renal Disease ◽  
Lupus Erythematosus ◽  
End Stage Renal Disease ◽  
Elevated Serum ◽  
Systemic Lupus ◽  
Histological Transformation ◽  
Stage Renal Disease ◽  
End Stage

Objective The understanding of systemic lupus erythematosus (SLE) and lupus nephritis (LN) pathogenesis remains incomplete. This review assessed LN development in SLE, within-LN progression and progression to end-stage renal disease (ESRD). Methods A keyword-based literature search was conducted, and 26 publications were included. Results Overall, 7–31% of patients had LN at SLE diagnosis; 31–48% developed LN after SLE diagnosis, most within 5 years. Class IV was the most commonly found LN class and had the worst prognosis. Histological transformation occurred in 40–76% of patients, more frequently from non-proliferative rather than proliferative lesions. Cumulative 5- and 10-year ESRD incidences in patients with SLE were 3% and 4%, respectively, and 3–11% and 6–19%, respectively, in patients with SLE and LN. Conclusions Elevated serum creatinine was identified as a predictor of worsening disease state, and progression within LN classes and from SLE/LN to ESRD. This review highlights the substantial risk for developing LN and progressing to ESRD amongst patients with SLE.

Tacrolimus versus cyclophosphamide as treatment for diffuse proliferative or membranous lupus nephritis: a non-randomized prospective cohort study

Lupus ◽  
2012 ◽  
Vol 21 (9) ◽  
pp. 1025-1035 ◽  
Author(s):  
S Wang ◽  
X Li ◽  
L Qu ◽  
R Wang ◽  
Y Chen ◽  
...  
Keyword(s):  
Lupus Nephritis ◽  
Renal Disease ◽  
Lupus Erythematosus ◽  
Activity Index ◽  
Disease Activity Index ◽  
Severe Adverse Effect ◽  
Open Label ◽  
Severe Renal Disease ◽  
Stage Renal Disease ◽  
End Stage

Treatment of lupus nephritis (LN) with cyclophosphamide (CYC) is effective but retains a certain severe adverse effect. Tacrolimus (TAC) may be a suitable treatment for LN. Forty patients with diffuse proliferative or membranous LN were recruited for this non-randomized open-label study — 67.5% (27/40) had nephrotic proteinuria (>3.5 g/day) and 50.0% (20/40) had low estimated glomerular filtration rate (eGFR) (<60 mL/min/1.73m2). We compared the efficacy and adverse effects of TAC (0.04–0.08 mg/kg/d)/prednisone for 12 months (TAC group, n = 20) with intravenous CYC (750 mg/m2 per month)/prednisone for six months followed by azathioprine (Aza) (100 mg/day)/prednisone for six months (CYC group, n = 20). The TAC target concentration was 6–8 ng/mL or 4–6 ng/mL, respectively, when induction or maintenance therapy was required and 4.0 ng/mL for patient with renal insufficiency. In the TAC group, mean urinary protein excretion decreased significantly from 5.00 ± 1.91 g/day at baseline to 2.54 ± 1.68 g/day after two weeks of therapy ( P < 0.001), compared with the CYC group (4.9 ± 19.4 g/day), P = 0.001, and 65.0% (13/20) achieved partial remission at one month, compared with the CYC group (0/20), P < 0.001. The incidence of complete remission (CR) was significantly higher in the TAC group than in the CYC group (55.0% vs.15.0% by five months, P = 0.008, and 75.0% vs.40.0% by 12 months, P = 0.025, respectively). The significant improvement in serum anti-dsDNA and systemic lupus erythematosus (SLE) disease activity index (DAI) was in the TAC group relative to the CYC group at 12 months ( P = 0.031, P = 0.003, respectively). The eGFR improved in the TAC group from 59.90 ± 23.64 mL/min/1.73m2 at baseline to 93.75 ± 28.52 mL/min/1.73m2 after 12 months, P = 0.001. In the CYC group, two patients developed end-stage renal disease (ESRD), three patients experienced serious pneumonia, and one patient died. Our preliminary study showed TAC is a safe and effective treatment for LN with severe renal disease, and with less-severe adverse events compared with CYC followed Aza therapy. Further larger sample studies are needed to confirm our conclusion.

scholarly journals XAF1 is identified as a novel hub gene and associated with the clinical characteristics of lupus nephritis

2020 ◽  
Author(s):  
Xingruo Zeng ◽  
Tian Xie ◽  
Jiaxing Sun ◽  
Yufei Lei ◽  
Lin Jia ◽  
...  
Keyword(s):  
Lupus Nephritis ◽  
Correlation Analysis ◽  
Clinical Features ◽  
Lupus Erythematosus ◽  
Kidney Tissue ◽  
Gene Expression Omnibus ◽  
Hub Genes ◽  
Hub Gene ◽  
Urgent Task ◽  
Microarray Expression

Abstract Background Lupus nephritis (LN) is a severe complication of systemic lupus erythematosus (SLE) that is the most common cause of morbidity and mortality. At present, the definitive therapies towards LN remains to be elucidated, so illuminating the molecular mechanism behind the disease has become an urgent task for researchers. This study set out to screen the hub genes of LN. Methods The microarray expression profile dataset GSE32591 from the Gene Expression Omnibus (GEO) database with 15 normal and 32 LN samples was assessed in this study. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were conducted on the LN-related differentially expressed genes (DEGs). The Nephroseq database was performed to identify correlation analysis between unexplored hub genes and clinical features of LN. Additionally, the expression of the candidate genes was detected in the kidney tissue by immunohistochemistry. Results The 14 genes (13 upregulated and 1 downregulated) ultimately screened out as candidate hub genes of the pathogenesis of LN. Moreover, Correlation analysis between the unexplored hub genes and clinical features of LN suggested that XAF1 may involve in the progression of LN. Finally, our data demonstrated that the expression level of XAF1 was upregulated in LN compared with IgA nephropathy (IgAN) and related to the WHO Lupus Nephritis Class and the quantitative 24 h proteinuria of LN patients. Conclusions The current study proposed XAF1 as a novel hub gene in LN which may perform as a brand-new biomarker or therapeutic target of LN in the future.

scholarly journals Management of Lupus Nephritis

2021 ◽  
Vol 10 (4) ◽  
pp. 670
Author(s):  
Farah Tamirou ◽  
Frédéric A. Houssiau
Keyword(s):  
Kidney Disease ◽  
Lupus Nephritis ◽  
Lupus Erythematosus ◽  
Randomized Trials ◽  
Treatment Strategies ◽  
Sequential Therapy ◽  
Current Treatment ◽  
Treat To Target ◽  
Severe Manifestation ◽  
End Stage

Lupus nephritis (LN) is a frequent and severe manifestation of systemic lupus erythematosus. The main goal of the management of LN is to avoid chronic kidney disease (CKD). Current treatment strategies remain unsatisfactory in terms of complete renal response, prevention of relapses, CKD, and progression to end-stage kidney disease. To improve the prognosis of LN, recent data suggest that we should (i) modify our treat-to-target approach by including, in addition to a clinical target, a pathological target and (ii) switch from conventional sequential therapy to combination therapy. Here, we also review the results of recent controlled randomized trials.

scholarly journals A review of advances in the understanding of lupus nephritis pathogenesis as a basis for emerging therapies

F1000Research ◽  
2020 ◽  
Vol 9 ◽  
pp. 905
Author(s):  
Susan Yung ◽  
Desmond YH Yap ◽  
Tak Mao Chan
Keyword(s):  
Lupus Nephritis ◽  
B Cell ◽  
Signaling Pathways ◽  
Lupus Erythematosus ◽  
Kidney Injury ◽  
Response To Treatment ◽  
Emerging Therapies ◽  
Specific Antigens ◽  
Stage Renal Disease ◽  
End Stage

Lupus nephritis is an important cause of both acute kidney injury and chronic kidney disease that can result in end-stage renal disease. Its pathogenic mechanisms are characterized by aberrant activation of both innate and adaptive immune responses, dysregulation of inflammatory signaling pathways, and increased cytokine production. Treatment of lupus nephritis remains a challenging issue in the management of systemic lupus erythematosus since the clinical presentation, response to treatment, and prognosis all vary considerably between patients and are influenced by ethnicity, gender, the degree of chronic kidney damage, pharmacogenomics, and non-immunological modulating factors. Elucidation of the various immunopathogenic pathways in lupus nephritis has resulted in the development of novel therapies, including biologics that target specific antigens on B lymphocytes to achieve B cell depletion, agents that modulate B cell proliferation and development, drugs that block co-stimulatory pathways, drugs that target T lymphocytes primarily, and therapies that target complement activation, signaling pathways, pro-inflammatory cytokines, and neutrophil extracellular traps. This review will discuss recent advances in the understanding of disease pathogenesis in lupus nephritis in the context of potential emerging therapies.

scholarly journals A lupus nephritis kezelésének irányelvei, valamint a mycofenolat mofetil hatékonyságának bemutatása intézetünk lupus nephritises betegeinek körében

2016 ◽  
Vol 157 (35) ◽  
pp. 1385-1393
Author(s):  
Melinda Zsuzsanna Szabó ◽  
Emese Kiss
Keyword(s):  
Lupus Nephritis ◽  
Lupus Erythematosus ◽  
End Stage Renal Disease ◽  
Remission Induction ◽  
Class Iii ◽  
Systemic Lupus ◽  
Single Centre ◽  
Life Threatening ◽  
Stage Renal Disease ◽  
End Stage

The authors present the latest guideline for the treatment of lupus nephritis and their own single-centre results with mycofenolate mofetil treated lupus nephritis. Lupus nephritis and mainly its proliferative form is a frequent and potentially life-threatening manifestation of systemic lupus erythematosus that can lead to end-stage renal disease. The treatment of lupus nephritis greatly improved in the last decades; mycofenolate mofetil has become an alternative of cyclophosphamide both in remission induction and as a maintenance regimen as well in the treatment of Class III and IV glomerulonephritis. The authors ordered mycofenolate mofetil for 25 patients with lupus nephritis so far. Histologically most of them had Class III (A/C) or IV (A) glomerulonephritis (30–30%), and only 16% of the patients had renal impairment at that time. Mycofenolate mofetil given after glucocorticoid and cyclophosphamide induction therapy reduced the daily proteinuria from 3.18 grs to 1.06 grs. Complete remission could be achieved in 24% and partial remission in 48% of the patients. The authors conclude that mycofenolate mofetil is effective in the therapy of lupus nephritis. Orv. Hetil., 2016, 157(35), 1385–1393.

Sign in / Sign up

Export Citation Format

Share Document